Literature DB >> 3712378

Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase.

L I Kruse, C Kaiser, W E DeWolf, J S Frazee, R W Erickson, M Ezekiel, E H Ohlstein, R R Ruffolo, B A Berkowitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3712378     DOI： 10.1021/jm00156a002

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  7 in total

1.  Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat.

Authors:  Nuno Miguel Pires; Bruno Igreja; Eduardo Moura; Lyndon Christopher Wright; Maria Paula Serrão; Patrício Soares-da-Silva
Journal:  Hypertens Res       Date:  2015-04-09       Impact factor: 3.872

2.  Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat.

Authors:  Bruno Igreja; Nuno Miguel Pires; Maria João Bonifácio; Ana Isabel Loureiro; Carlos Fernandes-Lopes; Lyndon Christopher Wright; Patrício Soares-da-Silva
Journal:  Hypertens Res       Date:  2014-10-09       Impact factor: 3.872

3.  Interaction of dopamine beta-mono-oxygenase with substituted imidazoles and pyrazoles. Catalysis and inhibition.

Authors:  S R Sirimanne; H H Herman; S W May
Journal:  Biochem J       Date:  1987-02-15       Impact factor: 3.857

Review 4.  Selenium-based antihypertensives. Rationale and potential.

Authors:  S W May; S H Pollock
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

5.  Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitor.

Authors:  Ana I Loureiro; Jose F Rocha; Carlos Fernandes-Lopes; Teresa Nunes; Lyndon C Wright; Luis Almeida; Patricio Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

6.  Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects.

Authors:  Teresa Nunes; José F Rocha; Manuel Vaz-da-Silva; Bruno Igreja; Lyndon C Wright; Amílcar Falcão; Luis Almeida; Patricio Soares-da-Silva
Journal:  Drugs R D       Date:  2010

7.  New Inhibitors of Laccase and Tyrosinase by Examination of Cross-Inhibition between Copper-Containing Enzymes.

Authors:  Dinesh Chaudhary; Fangchen Chong; Trilok Neupane; Joonhyeok Choi; Jun-Goo Jee
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.